CVS Health to return $43M in coronavirus funds

Amy Baxter | | Health Exec | Policy & Regulations

CVS Health has stated it will return $43 million in funding it received for COVID-19 relief, CNN Business reported. The company received the funds from the federal government as part of the CARES Act Provider Relief Fund, which offered $175 billion to hospitals and healthcare providers to aid in the COVID-19 response.

CVS Health CEO Larry Merlo penned a letter to HHS Secretary Alex Azar to return the funds and decline any further compensation from the government.

“We have made the decision to return the funds and forgo participation in subsequent disbursements," Merlo wrote in the letter, as cited by CNN Business. "In doing so, we hope to help HHS provide additional support to other providers who are facing significant financial challenges as a result of the pandemic."

CVS Health has been ramping up its COVID-19 testing capabilities as part of its response to the pandemic, adding more sites over the last two months and waiving costs for its Aetna members. Aetna is owned by CVS Health.

See the full story below:

CVS Health is returning $43 million in coronavirus relief funds

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.